Biomarkers /
RAD51C
Overview
RAD 51 paralog C (RAD51C) is a gene that encodes a protein that functions in the homologous recombination and repair of DNA. Missense mutations, silent mutations, and frameshift deletions are observed in cancers such as cancers of the biliary tract, endometrial cancer, and intestinal cancer.
RAD51C is altered in 1.23% of all cancers with breast invasive ductal carcinoma, invasive breast carcinoma, lung adenocarcinoma, bladder urothelial carcinoma, and colon adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in RAD51C are RAD51C Mutation (0.59%), RAD51C Amplification (0.69%), RAD51C Nonsense (0.07%), RAD51C Fusion (0.02%), and RAD51C Loss (0.02%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of RAD51C in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.